Clinical trials: Sadness
Healthy Volunteers
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers
The goal of this clinical trial was to learn about the safety and tolerability of an investigational drug called Benfo-oxythiamine (B-OT) in healthy male volunteers.
- Trial name
- BOOST (NCT07450833)
- Testing
- Benfo-oxythiamine
- Where
- Bulgaria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Benfovir AG
PNH
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
This is a single site, single dose escalation study in healthy subject with CAN106. The study is to assess the safety and tolerability of single escalating doses of CAN106; to characterize the PK and PD profile of CAN106; and to…
- Trial name
- NCT05095168
- Testing
- CAN106
- Where
- Singapore
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- CARE Pharma Shanghai Ltd.
Pregnancy Related, Postpartum Sadness
Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women
The postpartum period is a critical time for both maternal and child health, and more than half of all maternal deaths occur postpartum, from one day to one year after birth.
- Trial name
- NCT04475718
- Testing
- Fourth Trimester Mobile Tool
- Where
- 2 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Carelon Research
Healthy Volunteers
First-in-Human Single and Multiple Dose of EB8018
The purpose of this study is to determine the safety profile of single and multiple doses of EB8018 in healthy male subjects, to determine the pharmacokinetic profile of single and multiple doses of EB8018 in healthy male…
- Trial name
- NCT02998190
- Testing
- Single Ascending Doses of EB8018, Multiple Ascending Doses of EB8018
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Enterome
Healthy
A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
The purpose of this First-in-Human study is to evaluate the safety , tolerability，PK and PD after single ascending of HNC664 given to healthy subjects, compared to placebo. Also, food effect will be evaluated.
- Trial name
- NCT04504448
- Testing
- HNC664 capsules Single dose, HNC664 capsules FED
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Depression
The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression
There is good evidence to suggest that the pathological version of sadness that people with Major Depression experience could be caused by the failure of the hormone cortisol to properly inhibit sadness-related brain activity in…
- Trial name
- NCT02837432
- Testing
- Hydrocortisone acetate
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Stanford University
Healthy
Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy Subjects
The purpose of this study is to evaluate the safety and tolerability of NKTR-118 with healthy subjects.
- Trial name
- Japan SMAD (NCT01318655)
- Testing
- NKTR-118
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406
The study is designed as a single center, randomized, double-blind, placebo-controlled study to assess the PK, safety, tolerability and PD of CB-0406 in healthy participants. The study will be conducted as a 2-part study.
- Trial name
- NCT04467684
- Testing
- CB-0406 100 mg, CB-0406 200 mg, CB-0406 400 mg
- Where
- Australia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Healthy Volunteers
A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers
This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of ALTB-268 in healthy volunteers.
- Trial name
- NCT05723692
- Testing
- ALTB-268
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- AltruBio Inc.
Social Anxiety Disorder
Geodon for the Treatment of Refractory Social Anxiety Disorder
The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment…
- Trial name
- SAD (NCT00215150)
- Testing
- Ziprasidone, Sertraline
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Duke University
Healthy
Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants
The present study in healthy participants will assess the safety, tolerability, immunogenicity, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) of subcutaneously administered M5542.
- Trial name
- NCT06577337
- Testing
- M5542
- Where
- Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Social Anxiety Disorder, Body Dysmorphic Disorder
Individual Factors of CBT Underlying Success
The purpose of this study is to understand why some individuals respond fully to cognitive behavioral therapy and others do not, based on multiple sources of data such as neural, neurocognitive, clinical, and self-report data.
- Trial name
- I-FOCUS (NCT06678295)
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Washington
Social Phobia
A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
To compare by neuroimaging techniques and public speaking, the way social anxiety patients respond after the administration of GW876008, GSK561679, alprazolam and placebo
- Trial name
- NCT00555139
- Testing
- GSK561679 tablet, GW876008 tablet, alprazolam
- Where
- 8 sites in Spain
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Healthy
Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants
The current study is the second clinical administration with PF-07304814, the phosphate prodrug of the active moiety PF-00835231, and the first in healthy adult participants.
- Trial name
- NCT04627532
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
Single and Multiple Ascending Dose Study of TD-8236 by Inhalation
This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 3 parts: Part A is a single ascending dose (SAD) study in healthy subjects, Part B is a multiple ascending dose (MAD) study in…
- Trial name
- NCT03652038
- Testing
- TD-8236
- Where
- 2 sites in United Kingdom
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Social Anxiety Disorder
Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)
The purpose of the study is to determine whether the PH94B nasal spray is effective for Acute Treatment of the symptoms of Social Anxiety Disorder (SAD) in adult men and women.
- Trial name
- NCT02622958
- Testing
- PH94B
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Pherin Pharmaceuticals, Inc.
Healthy Volunteers
SAD and MAD Study of FTX-101 in Healthy Male Subjects
This is a Phase 1, first-in-human (FIH), single-center, randomized, double-blind, placebo-controlled study in healthy male subjects.
- Trial name
- NCT06617546
- Testing
- FTX-101
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Find Therapeutics
Phobia, Social
Gaze Contingent Feedback in Social Anxiety Disorder
The purpose of this study is to determine whether giving gaze-contingent feedback is an effective attention modification procedure, helping in the treatment of social anxiety disorder (SAD)
- Trial name
- NCT02590770
- Testing
- attention modification
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Tel Aviv University
Healthy Volunteers - Male and Female
A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers
This is a Phase 1, First-Time-In-Humans, randomized, placebo-controlled, double-blind, escalating single- and multiple-dose study to evaluate the safety, tolerability, and pharmacokinetics of CNM-Au8 in healthy male and female…
- Trial name
- NCT02755870
- Testing
- CNM-Au8
- Where
- Netherlands
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Clene Nanomedicine
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc